Les portefeuilles pharmaceutiques et de dispositifs médicaux de Johnson & Johnson sont bien positionnés pour bénéficier du vieillissement des populations stimulant la demande accrue en traitements oncologiques, immunologiques et chirurgicaux.
Johnson & Johnson est une valeur de premier ordre typique avec plus de 130 ans d'historique opérationnel, une cote de crédit AAA détenue par très peu de sociétés, et une activité de santé diversifiée qui assure la stabilité à travers pratiquement n'importe quel cycle économique.
Johnson & Johnson est un géant de la santé avec plus de 60 années consécutives d'augmentations de dividendes, ancré par des franchises pharmaceutiques et de dispositifs médicaux de premier plan sur les marchés mondiaux.
Johnson & Johnson est une Dividend King avec plus de 60 années consécutives d'augmentations de dividendes annuels, soutenue par les flux de trésorerie stables et résistants aux récessions de ses activités pharmaceutiques et de dispositifs médicaux. Son long historique de croissance fiable des dividendes en fait une valeur de dividende de premier plan pour les investisseurs à la recherche de revenus stables du secteur de la santé.
Data updated Feb 15 · Source: Twelve Data
Johnson & Johnson remains one of the most dependable names in healthcare investing. Following its Kenvue consumer health spinoff, JNJ is now a focused pharmaceutical and MedTech company, better positioned to capitalize on aging demographics through oncology, immunology, and surgical innovations.
The stock has surged nearly 57% over the past year, now trading near its 52-week high of $246.35 and well above its 50-day moving average. This rally has stretched the P/E ratio to 32.37"elevated relative to historical norms"raising valuation concerns for new entrants. EPS of $7.52 reflects solid but not exceptional earnings power.
As a Dividend Aristocrat with 60+ consecutive years of increases, JNJ's income reliability is unmatched, though the current yield has compressed due to price appreciation. The pharmaceutical pipeline, including Darzalex and Tremfya, provides meaningful growth catalysts, while MedTech benefits from procedure volume recovery.
Key risks include ongoing talc litigation liabilities, patent cliffs on major drugs, and the premium valuation. The bull case centers on pipeline execution, demographic tailwinds, and defensive positioning during economic uncertainty. A strong core holding, though dollar-cost averaging may be prudent at current levels.
Johnson & Johnson remains a definitive blue-chip holding, recently demonstrating robust momentum as it trades near its 52-week high of $240.94. Following its strategic restructuring to focus on high-growth pharmaceutical and MedTech segments, the stock has surged well above its 50-day moving average. However, the current valuation warrants caution; at a P/E ratio of 31.70, JNJ is trading at a significant premium to its historical range, suggesting that optimistic growth expectations are already priced in. While the company's legendary status as a Dividend King continues to attract income investors seeking stability, the stretched multiple may limit near-term upside. JNJ represents a high-quality defensive play with a fortress balance sheet, but value-conscious investors might prefer to wait for a pullback before adding to positions.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Chaque trader a une stratégie qui semble excellente dans sa tête. Le backtesting est la façon de découvrir si cela fonctionne réellement. Voici comment tester les stratégies correctement, quelles métriques comptent et pourquoi la plupart des résultats de backtesting sont trop beaux pour être vrais.
Powered by Rexiew